An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating seizures for a long period of time in patients with epilepsy (aged 16 years or older)

An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (≥16 years to 80 years)

Registry ID

EUCTR2010-020345-27

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

UCB BIOSCIENCES, INC.

Start date

2013-10-07

Completion date

2019-04-18

Last update

2026-08-16

Conditions

• Focal Epilepsy
• Crisis de inicio parcial
• Epilepsy
• Partial onsetseizure

Summary

To evaluate the long-term safety and tolerability of BRV at individualized doses up to a maximum of 200mg/day in epilepsy subjects.

Locations

• , , Sweden
• , , Belgium
• , , Czechia
• , , Spain
• , , France
• , , UK
• , , Germany
• , , Austria
• , , Finland
• , , Netherlands
• , , Italy
• , , Estonia
• , , Lithuania
• , , Latvia
• , , Hungary
• , , Bulgarian Drug Agency

Related clinical trials

• Optimizing epilepsy surgery
• Normative and Clinical Validation Study of Neuropsychological Tasks Implemented in EpiTrack Junior for the Assessment of Figural and Verbal Memory
• High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT
• Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
• LIFUS For Neurological Disorders
• Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

View on source registry